Molecular / review · PMID 34173097
Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease — VialBase Research
Recent compound-specific (KED) study broadening Vesugen's mechanism.
Last updated · 2021 · Khavinson VK et al. · Bull Exp Biol Med
Key findings
- The KED tripeptide (Vesugen) was linked to molecular-genetic regulation of neurogenesis
- Extends KED's regulatory profile beyond the vasculature into neural gene expression
Peptide KED and neurogenesis regulation (PMID: 34173097)
Summary
The KED tripeptide (Vesugen) was associated with molecular-genetic regulation of neurogenesis in an Alzheimer’s-disease context, extending its known vascular profile.
Relevance
Compound-specific (KED) evidence for Vesugen beyond endothelial effects.
See Also
- Parent compound: Vesugen